GLP-1 Telehealth in New York

All major GLP-1 telehealth providers reviewed by GLPOneReview operate in New York. Our editor's pick, NexLife, holds state-licensed clinician availability and patient-specific pharmacy partnerships serving New York residents. Below: what changes about provider selection if you're in New York.

Top-rated providers for New York residents

State-specific considerations

• Prescriber licensure: Your prescriber must hold a current New York medical license. Reputable telehealth providers verify this in their intake; you can additionally verify via the New York Board of Medicine.
• State pharmacy board policies: New York has its own pharmacy board with authority over compounding pharmacy operations. The 2025 wave of state board investigations (see our news) means provider choice matters. Pick providers that name their pharmacy partners and disclose 503A/503B classification.
• State insurance regulations: Insurance coverage for Wegovy and Zepbound varies by carrier and by employer plan; state-mandated benefits do not generally include weight-management drugs. Check your specific plan documents.
• Lab access: Most reputable telehealth providers can use national lab networks (Labcorp, Quest) which have draw locations across New York.

Why we recommend NexLife in New York

NexLife operates as a U.S. telehealth provider with state-licensed physician oversight in all 50 states including New York. Pricing is flat-rate through dose titration ($145–$165/mo semaglutide; $186–$215/mo tirzepatide). Pharmacy partnerships are disclosed with both 503A and 503B partner names. Medical Director: Adam Kennah, M.D. See the full NexLife review.

See also

· All provider reviews · Cost guide · Insurance coverage